NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available.

NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N. gonorrhoeae in men or women.

NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications. (See
DOSAGE AND ADMINISTRATION.)

NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil's lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents. (See
CLINICAL STUDIES
section.)

Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of VANTIN and other antibacterial drugs, VANTIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

NEWS HIGHLIGHTS

Published Studies Related to Vantin (Cefpodoxime Proxetil)

The comparative plasma pharmacokinetics of intravenous cefpodoxime sodium and oral cefpodoxime proxetil in beagle dogs. [2007.08]The pharmacokinetic properties of cefpodoxime, and its prodrug, cefpodoxime proxetil, were evaluated in two separate studies, one following intravenous (i.v.) administration of cefpodoxime sodium and the second after oral (p.o.) administration of cefpodoxime proxetil to healthy dogs... Combined with previous studies, these results suggest that a single daily oral dose of 5-10 mg cefpodoxime/kg body weight as cefpodoxime proxetil maintains plasma concentrations effective for treatment of specified skin infections in dogs.

Efficacy of cefpodoxime in the prophylaxis of recurrent pharyngotonsillitis. [2003.12]BACKGROUND: Recurrent acute pharyngotonsillitis remains a common illness in children and young adults and can lead to serious complications if not treated. cefpodoxime proxetil is a second-generation oral cephalosporin, which shows potent antibacterial activity against both Gram-positive and Gram-negative bacteria and high stability in the presence of beta-lactamases. OBJECTIVE: We aimed to evaluate the efficacy of second-generation cephalosporins in the prophylaxis of recurrent pharyngotonsillitis in children... CONCLUSIONS: Our results show that treatment with cefpodoxime proxetil may be effective in reducing symptoms of recurrent pharyngotonsillitis and preventing recurrences without causing side effects or developing bacterial resistance.

Clinical Trials Related to Vantin (Cefpodoxime Proxetil)

Cefpodoxime vs Ciprofloxacin for Acute Cystitis [Completed]
Urinary tract infection (UTI) is a very common problem in young healthy women, afflicting
approximately one-half of women by their late 20s. One of the most common antibiotics used
to treat UTIs is ciprofloxacin, usually for a total of three days. However, increasing
resistance to this antibiotic has raised concerns about its overuse for cystitis and
generated interest in alternative agents. An alternative antibiotic which is approved for
use in UTIs is cefpodoxime. However, there are few studies evaluating the efficacy and
tolerance of this compound when given in a 3-day regimen as is commonly used for treatment
of UTI. The major purpose of this study is to assess the efficacy and tolerance of a 3-day
regimen of cefpodoxime versus ciprofloxacin for treatment of acute uncomplicated cystitis.

Patients Response to Early Switch To Oral:Osteomyelitis Study [Not yet recruiting]
Based on the current literature, investigators hypothesize that patients with osteomyelitis
who are treated with the standard approach of intravenous antibiotics for the full duration
of therapy will have the same clinical outcomes as patients treated with the experimental
approach of intravenous antibiotics with early switch to oral antibiotics.
The primary objective of this study is to compare patients with osteomyelitis treated with
the standard approach of intravenous antibiotics for the full duration of therapy versus
patients treated with intravenous antibiotics with an early switch to oral antibiotics in
relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy.
Secondary objectives of the study include the evaluation of adverse events related to the
use of antibiotics as well as the cost of care evaluated from the hospital perspective.

Nut Allergy Study: Double-blind Challenge and Oral Desensitization [Recruiting]
Nut sensitization in skin prick tests is common in areas, including Finland, where birch
pollen is abundant. However, sensitization to nuts in skin prick test does not predict the
possibility of allergic symptoms when nuts are ingested. In this study the investigators
launch and perform double-blind placebo-controlled nut challenges and oral desensitization/
protocol to those with serious symptoms in the challenge. The efficacy and safety of the new
oral desensitization program is the primary outcome. The effect of oral desensitization on
bronchial hyperreactivity, eosinophilic airway inflammation, and quality of life are
secondary outcomes.